Osteocalcin, Serum
Use
Monitoring and assessing the effectiveness of antiresorptive therapy in patients treated for osteopenia, osteoporosis, Paget disease, or other disorders in which osteocalcin levels are elevated. As an adjunct in the diagnosis of medical conditions associated with increased bone turnover, including Paget disease, cancer accompanied by bone metastases, primary hyperparathyroidism, and renal osteodystrophy. Note that this test is not useful for the diagnosis of osteoporosis.
Special Instructions
Not provided.
Limitations
Measurements of bone turnover markers are not useful for the diagnosis of osteoporosis. Osteocalcin is cleared by the kidneys; elevations may be observed in patients with impaired kidney function without increased bone turnover. Serum osteocalcin may not reflect bone formation in patients treated with hormone 1,25-dihydroxy vitamin D due to its regulation by the hormone. Interference may occur due to animal antibodies (HAMA) or antibodies to streptavidin or ruthenium.
FDA ApprovedNew York Approved
Methodology
Immunoassay (ECLIA)
Biomarkers
LOINC Codes
- 2697-1 - Osteocalcin SerPl-mCnc
- 2697-1 - Osteocalcin SerPl-mCnc
Result Turnaround Time
1-3 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.75 mL
Container
Serum gel (preferred) or red top; submission in plastic vial
Collection Instructions
Centrifuge and aliquot serum into a plastic vial.
Patient Preparation
Fasting: 12 hours, required; avoid multivitamins or supplements with biotin for 12 hours.
Causes for Rejection
Gross hemolysis
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 72 hours |
| Refrigerated | 14 days |
| Frozen | 90 days |